Combination Therapy With Carfilzomib for the Antibody-Mediated Rejection Diagnosis in Lung Transplantation
Status:
Recruiting
Trial end date:
2021-12-01
Target enrollment:
Participant gender:
Summary
The clinical trial is a Phase II open label, single-arm pilot study to evaluate the safety
and efficacy of combination therapy with carfilzomib, plasma exchange and intravenous
immunoglobulins for AMR after lung transplantation and elucidate important clinical and
immunologic phenotypes and mechanisms associated with these outcomes.